Neurotrope (NTRP) Sets New 52-Week Low at $4.74
Neurotrope Inc (NASDAQ:NTRP) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $4.74 and last traded at $5.48, with a volume of 100 shares trading hands. The stock had previously closed at $5.66.
NTRP has been the subject of several research analyst reports. Maxim Group reaffirmed a “buy” rating and set a $16.00 price target on shares of Neurotrope in a research note on Monday, August 13th. Zacks Investment Research raised Neurotrope from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Friday, August 17th.
Neurotrope (NASDAQ:NTRP) last issued its quarterly earnings results on Tuesday, October 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.05.
WARNING: “Neurotrope (NTRP) Sets New 52-Week Low at $4.74” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/neurotrope-ntrp-sets-new-52-week-low-at-4-74/2671127.html.
Neurotrope Company Profile (NASDAQ:NTRP)
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C.
Featured Article: What is a Stop Order?
Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.